RE: RE: RE: RE: Comment on Seeking Alpha ArticleA detailed answer for a previous question about the sensitivity and specificity numbers for the preliminary 274 lesion study is detailed at the following link.
https://spie.org/x48133.xml?ArticleID=x48133
This is an excerpt:
Building on this progress, we analyzed data from 274 skin lesions including cancers (31 melanomas, 18 basal cell carcinomas, and 39 squamous cell carcinomas), precancerous lesions (20 actinic keratoses), and benign lesions (48 seborrheic keratoses and 118 various nevi). Rather than following specific molecules in skin and individual peaks of the Raman spectra,
we analyzed changes in the overall spectral shape. Our results showed that, by using Raman spectroscopy,
precancerous lesions and cancerous lesions can be differentiated from benign lesions with a sensitivity of 90% and specificity of 75%. Additionally,
melanomas are differentiated from other pigmented lesions
with nearly 100% sensitivity and 70% specificity.4 This is very encouraging for introducing Raman spectroscopy to clinical use. We have acquired in vivo Raman data from approximately 1000 skin lesions and are currently analyzing the data to develop an optimized algorithm for melanoma detection.
So to summarize: for all skin cancers (melanoma, BCC and SCC) sensitivity of 90% and specificity of 75%.
for melanoma: sensitivity is nearly 100%; specificity is 70%.
These results are from the preliminary 274 lesion study. We still await the full statistical analysis of the 1000 skin lesion sample to be published in a peer-reviewed journal.